Cytokinetics (CYTK) PT Raised to $33 at Piper Sandler, After Licensing Collaboration Announced
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $84.16 -2.22%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 17
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 17
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff raised the price target on Cytokinetics (NASDAQ: CYTK) to $33.00 (from $28.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cytokinetics (CYTK) PT Lowered to $117 at RBC Capital
- Vermilion Energy (VET:CN) (VET) PT Lowered to Cdn$22 at CIBC
- Quebecor (QBR/B-CN) (QBCRF) PT Raised to Cdn$78 at CIBC
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
